
Social challenges
IMPETUS
IMPETUS aims to set up a Citizen Science (CS) innovation programme to support and give recognition to citizen science in...
therapies
Decision on combinatorial therapies in immune-mediated diseases using systemic approaches
Project dates
2020-2025
Website
Role of Zabala
PARTNER
Project led by
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
10
Partners
6
Countries
6.2
M€ Budget
5
Years
Immune-mediated Inflammatory Diseases (IMIDs) are a group of diseases caused by inappropriate activation of the immune system in cells and organs. They are relatively common and affect up to 7% of the general population, being the third most common type of disease in developed countries. In the DoCTIS project, we focus on six of the most frequent IMIDs in our society: rheumatoid arthritis (RA), psoriasis (PsA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC) and systemic lupus erythematosus (SLE). In these six diseases, chronic activation of the powerful immune system ultimately affects the functionality of many tissues and organs, such as the joints in RA and PsA or the gut in CD and UC. This clearly reduces the quality of life of many patients, as well as increases the risk of other diseases and shortens life expectancy.
The last 20 years have seen a breakthrough in the development of therapies to treat IMIDs. These therapies have been an improvement over previous drugs, helping reduce the impact on a significant percentage of patients. However, many other patients do not respond adequately to these new therapies. Moreover, in many cases, these new therapies eventually lose efficacy and must be discontinued. These therapies are expensive and have become a major burden on European healthcare systems.
The DoCTIS project is designed to address this major health problem in IMIDs. To do this, we will identify new combinations of existing drugs that enhance the effect of each other. This combinatorial effect will have many beneficial aspects for IMID patients: it will reduce disease activity to remission (i.e. no symptoms), it will reduce the dose of the drugs (and thus the risk of toxicity) and, finally, it will reduce the likelihood of becoming resistant to therapy.
The DoCTIS project will integrate different experts from clinical, biological, computational and epidemiological fields. These experts will collaborate to generate and analyse high-throughput data generated from IMID patients, as well as animal models of the disease, to identify new drug combinations that are highly effective.
“Within the realm of IMIDs, the DoCTIS project emerges as a beacon of hope. Through the strategic identification of synergistic drug combinations, we aim to revolutionize treatment approaches”
Laura Sesma
Team leader expert in European Programmes in the Health Area
DocTIS, in the final stretch to revolutionize the treatment of immune-mediated inflammatory diseases
Social challenges
IMPETUS aims to set up a Citizen Science (CS) innovation programme to support and give recognition to citizen science in...
Industry
The main objective of MAGICIAN will be to develop robotic solutions which will identify and repair defects in manufacturing products...
Climate, Natural Resources and Environment
SHERPA aims to develop and validate innovative technologies for refurbishing current HPPs. The project will expand and/or adapt the operational...
News
Horizon 2020 project, CIRCUSOL, represented sustainable business models at the European Roundtable gathering solar power industry.
Opinion
Aerospace
Yann Poulain
Consultant
Publication
Universities
Find out which European grant programme for Universities best suits your project
The important thing is not to keep moving, but rather to know in which direction to go. Our 37% success rate proves that we know how to guide our clients.
Our compass is our clients; our mission is to solve their problems, guiding them so that innovation becomes their key to competitiveness.